Why the study?
It was unknown whether and to what extent ACEIs or ARBs affect the risk of developing AF after pacemaker implantation in very old patients.
Does daily oral use of ACEIs or ARBs reduce the risk of new-onset atrial fibrillation in very old patients after pacemaker implantation?
Does daily oral use of ACEIs or ARBs reduce the risk of new-onset atrial fibrillation in very old patients after pacemaker implantation?
In very old patients undergoing permanent pacemaker implantation, daily oral use of ARBs, but not ACEIs, is associated with a significantly reduced risk of developing new-onset atrial fibrillation.
Answers are grounded in this paper and cite their sources.
ARB use was associated with lower post-pacemaker AF risk in very old patients; leaves open whether randomized trials confirm benefit versus ACEIs.
It remains unknown whether and to what extend the angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) can play a role in the development of atrial fibrillation (AF) after pacemaker implantation in very old patients. Therefore, we aimed to investigate the association between oral ACEIs or ARBs and the risk of developing AF in very old patients after pacemaker implantation. Patients above 80 years old with pacemaker implantation and without baseline history of AF were included and their real-world information about ACEIs or ARBs use was extracted from electronic medical records. New AF cases were confirmed via the records of outpatient visits. The multivariable Cox proportional-hazards model was used to evaluate the associations between oral ACEIs or ARBs and risk of AF after pacemaker implantation. Among a total of 388 identified patients aged 80 to 98 years, 118 used ACEIs, 174 had ARBs therapy, and 115 AF were identified after pacemaker implantation during a median follow-up time of 3.1 years. After adjustment for potential confounders, patients with daily use of ARBs had a relatively lower risk of AF after pacemaker implantation (HR: 0.627, 95% CI: 0.425, 0.926; P = 0.019) compared with those non-users, whereas ACEIs therapy didn't show a significant relation with AF risk (HR: 1.335, 95% CI: 0.894, 1.995; P = 0.157). In conclusion, for very old patients with a permanent pacemaker, daily use of oral ARBs was associated with a relative lower risk of AF after pacemaker implantation, however, daily use of ACEIs was not related with AF risk.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: